IO Biotech’s Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

All NewsAugust 11, 2025

IO Biotech’s Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most subgroups.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

IO Biotech’s Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

The UCW Newswire : Financial, Business and Tech News

Recent Headlines

Walmart’s 3-piece microfiber comforter set that comes in 17 colors is just $44

Walmart’s 30-gallon deck box is $27 just in time for off-season storage

Crypto ally Tom Emmer elected House GOP minority whip

Macy’s $500 diamond circle pendant is on sale for 65% off

Factory automation has hidden problem companies cannot ignore